促销时间表 Bluebird Bio
先进的时间表
简单图表
关于公司 Bluebird Bio
Bluebird bio, Inc., биотехнологическая компания, исследует, разрабатывает и коммерциализирует трансформирующие генные методы лечения тяжелых генетических заболеваний и рака. Его продукты-кандидаты для лечения тяжелых генетических заболеваний включают betibeglogene autotemcel для лечения зависимой от переливания крови ß-талассемии; ЛентиГлобин для лечения серповидно-клеточной анемии; и эливальдоген аутотемцел для лечения церебральной адренолейкодистрофии. 更多详情| IPO date | 2013-06-19 |
|---|---|
| ISIN | US09609G1004 |
| Industry | Biotechnology |
| Sector | Health Care |
| Валюта | usd |
| Валюта отчета | usd |
| Див.доход ао | 0 |
| Сайт | http://www.bluebirdbio.com |
| Цена ао | 3.86 |
| 每日价格变化: | 0% (3.86) |
|---|---|
| 每周价格变化: | -6.08% (4.11) |
| 每月价格变化: | -36.2% (6.05) |
| 3个月内价格变化: | -49.21% (7.6) |
| 六个月内的价格变化: | +537.17% (0.6058) |
| 每年价格变化: | -85.49% (26.6) |
| 3年内价格变化: | -8.75% (4.23) |
| 5年内价格变化: | -91.52% (45.54) |
| 10年价格变化: | -90.67% (41.36) |
| 年初以来价格变化: | -50.45% (7.79) |
|
|
低估
|
效率
|
|||||||||||||||||||||||||||||||||||||
股息
|
责任
|
成长冲动
|
|||||||||||||||||||||||||||||||||||||
| 机构 | 体积 | 分享, % |
|---|---|---|
| State Street Corporation | 13865719 | 12.68 |
| Blackrock Inc. | 8983001 | 8.22 |
| Vanguard Group Inc | 8775379 | 8.03 |
| Granahan Investment Management LLC | 8077697 | 7.39 |
| Alyeska Investment Group, L.P. | 6912502 | 6.32 |
| Pictet Asset Management Holding SA | 5687334 | 5.2 |
| Norges Bank Investment Management | 3995600 | 3.65 |
| Millennium Management LLC | 3413612 | 3.12 |
| Palo Alto Investors Lp | 3333333 | 3.05 |
| Ghisallo Capital Management, LLC | 3150000 | 2.88 |
| ETF | 分享, % | 本年盈利能力, % | 股息, % |
|---|---|---|---|
| Direxion Low Priced Stock ETF | 2.79 | 0 | 0.02 |
| ProShares UltraShort Nasdaq Biotechnology | 0.65 | -40.36 | 1.76 |
| Global X Genomics & Biotechnology ETF | 0.15676 | 2.58 | 0.15585 |
| iShares Micro-Cap ETF | 0.02282 | 17.09 | 1.54048 |
| Invesco Nasdaq Biotechnology ETF | 0.00902 | 28.58 | 0.8565 |
| Principal Healthcare Innovators ETF | 0.00822 | 618.5 | 0.8416 |
| Future Tech ETF | 0.00822 | 426.34 | 0.8416 |
| ProShares Ultra Nasdaq Biotechnology | 0.00626 | 51.7 | 0.85651 |
| Motley Fool Next Index ETF | 0.00547 | 23.87 | 0.61129 |
ProShares UltraPro Russell2000
|
0.00195 | 89.82 | 1.47873 |
| ProShares Hedge Replication ETF | 0.00058 | 5.92 | 1.47892 |
| Dimensional U.S. Core Equity 2 ETF | 0.00037 | 30.76 | 1.47098 |
| Dimensional U.S. Equity ETF | 0.00006 | 31.53 | 1.3557 |
| iShares Russell 3000 ETF | 0.00006 | 24.83 | 1.43482 |
| Vanguard Russell 2000 ETF | 0 | 17.16 | 1.48801 |
| Vanguard Russell 3000 ETF | 0 | 31.87 | 1.43817 |
| 0.23 | 85.01 | 1.1 |
| 导师 | 职称 | 支付 | 出生年份 |
|---|---|---|---|
| Mr. Andrew Obenshain | President, CEO & Director | 1.04M | 1974 (51 年) |
| Mr. Thomas J. Klima | Chief Commercial Officer & COO | 654.97k | 1972 (53 年) |
| Ms. Andrea Walton | Chief People Officer | N/A | |
| Mr. Kasra Kasraian | Senior Vice President of Technical Development & Operations | N/A | |
| Mr. Joseph D. Vittiglio Esq., J.D. | Chief Legal & Business Officer and Secretary | N/A | 1972 (53 年) |
| Jess Rowlands | Head of Corporate Communications | N/A | |
| Mr. Scott Shoemaker | Senior Vice President of Quality | N/A | |
| Mr. Richard A. Colvin M.D., Ph.D. | Chief Medical Officer | 696.24k | 1966 (59 年) |
| Ms. Sarah Alspach | Senior Vice President of External Affairs | N/A | |
| Mr. Oliver James Sterling III | CFO & Principal Accounting Officer |
地址: United States, Cambridge, MA , 60 Binney Street - 在 Google 地图中打开, 打开 Yandex 地图
网站: http://www.bluebirdbio.com
网站: http://www.bluebirdbio.com
